MedPath

Incremental Vestibulo-ocular Reflex Adaptation As a Novel Treatment for Dizziness in People with Multiple Sclerosis

Not Applicable
Recruiting
Conditions
Multiple Sclerosis
Interventions
Device: StableEyes
Registration Number
NCT06495138
Lead Sponsor
Emory University
Brief Summary

The study aims to study the effects of a novel treatment for vestibular symptoms in people with multiple sclerosis. The main objective is to determine whether daily personalized gaze stabilization training is more beneficial than intermittent gaze stability training in people with multiple sclerosis.

Detailed Description

People with multiple sclerosis (MS) often experience dizziness, caused by problems in how their brain processes balance signals. This dizziness can lead to difficulties keeping their eyes focused on a target while moving their head, known as gaze instability. This makes activities like walking or driving challenging and dangerous. Vestibular physical therapy, including gaze stabilization exercises, can help. The team developed StableEyes, a technology that improves gaze stability using a gradual approach to these exercises. In the studies, StableEyes significantly enhanced gaze stability in people with balance issues. Preliminary research in people with MS shows promising results, suggesting that tailored gaze stability exercises can further improve their vision stability. This method targets the vestibulo-ocular reflex (VOR), a critical reflex for maintaining clear vision during head movements. Improved VOR function can reduce dizziness and improve the quality of life for people with MS.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
138
Inclusion Criteria
  • Neurologist-confirmed diagnosis of primary progressive or relapsing and remitting MS per the 2017 Revision of the McDonald Criteria and the Magnetic Resonance Imaging in MS
  • Fluent in speaking and understanding English
  • Have self-reported vestibular symptoms of dizziness, imbalance, and/or a history of at least two falls in the prior 12 months
Exclusion Criteria
  • Clinically isolated syndrome or radiologically isolated syndrome.
  • Worsening MS symptoms during the prior 60 days
  • Immunotherapy change in the prior 60 days
  • Self-reported cognitive impairment that limits independence with basic and instrumental activities of daily living
  • Systolic blood pressure > 180 mmHg and/or diastolic blood pressure > 90 mmHg at rest
  • Static visual acuity with correction of worse than 1.0 logMAR
  • Manifest ocular misalignment ≥ 5 diopters (e.g., tropia, lazy eye, strabismus}
  • Convergence insufficiency
  • Intra-nuclear ophthalmoplegia
  • Benign paroxysmal positional vertigo
  • Major orthopedic conditions that limit cervical spine range of motion or that alter walking
  • Self-reported current or potential for pregnancy during enrollment
  • Ongoing participation in vestibular rehabilitation for dizziness

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Daily Incremental Vestibulo-ocular Reflex Adaptation (D-IVA-GSE)StableEyesThe dosages of the D-IVA-GSE and I-IVA-GSE are based on the FITT principle of exercise prescription (frequency, intensity, time, and type). The D-IVA-GSE group will perform two, 15- minute GSE sessions (30-minutes total per day), seven days per week.
Intermittent incremental vestibulo-ocular Reflex Adaptation (I-IVA-GSE)StableEyesThe I-IVA-GSE group will perform two, 15-minute IVA-GSE sessions (30 minutes total), three days per week, with at least one day between each exercise day.
Primary Outcome Measures
NameTimeMethod
Composite VOR gain (cVOR gain)Weeks 1,4, 7, and 18

The team will conduct the video head impulse test (vHIT), a physiologic assay of vestibular semicircular canal pathway function. Angular vestibulo-ocular reflex gain will be calculated as eye velocity / head velocity during self-generated and/or passive high frequency head rotations which will be conducted in the yaw, pitch, roll, and/or semicircular canal planes.

Secondary Outcome Measures
NameTimeMethod
Best Corrected Dynamic Visual Acuity (During Head Movements)Weeks 1, 4, 7, and 18

The ability of participants to see clearly while their head is in motion (e.g., during self-generated head movements while seated, while walking at their preferred walking speed) will be assessed using commercially available hardware and custom software while the participant's head is moving.

Dizziness Handicap Inventory Total ScoreWeeks 1, 4, 7, and 18

The DHI be used to assess participants' perceived level of handicap due dizziness. This measure consists of 25 questions that are answered as "yes" = 4 points (dizziness is always a factor), "sometimes" = 2 points (dizziness is sometimes a factor), or "no" = 0 points (dizziness is never a factor) for a given situation or issue. The maximum total score on this measure is 100 points with higher scores indicating higher levels of perceived handicap.

Activities-specific Balance Confidence Scale Average ScoreWeeks 1, 4, 7, and 18

The ABCS consists of 16 questions for which the respondent answers how confident they feel in not becoming unsteady or falling in specific situations. Confidence is rated on a scale of 0% to 100% with 0% indicating "no confidence" and 100% indicating "complete confidence' in the ability to maintain balance. Average scores of ≥ 80% are associated with high levels of physical functioning in adults.

Balance Evaluation Systems Test Total ScoreWeeks 1, 4, 7, and 18

The BEST will be instrumented using inertial measurement units (IMU) placed at the head, upper torso, pelvis, and both ankles. The BEST is a 36-item assessment of the body systems that contribute to balance and walking. Total scores range from 0 to 108 points

Multiple Sclerosis Quality of Life - 54 (MSQOL-54) Total ScoreWeeks 1, 4, 7, and 18

The MSQOL-54 is a multidimensional measure that consists of questions related to general and MS-specific health-related quality of life. The MSQOL-54 was created by adding 18 items related to MS-specific issues, e.g., fatigue and cognitive function.

Gait Disorientation Test (GDT) ScoreWeeks 1, 4, 7, and 18

The GDT is a 2-item assessment of aspects of spatial navigation. Task 1 is to walk 20 feet with eyes open. Task 2 is to walk 20 feet with eyes closed. Both tasks are timed, and the GDT result is the time needed to walk with eyes closed minus the time needed to walk with eyes open.

Oscillopsia Visual Analog Scale ScoreWeeks 1, 4, 7, and 18

Visual analog scales are commonly used in clinical practice and research. The investigator will measure the severity of oscillopsia (unstable vision during head movement) and sense of disequilibrium while the participant walks 20' on separate visual analog scales. The distance from the zero anchor to the respondent's marking will be measured without units but to the nearest tenth. The response for each scale will be transformed to a 100-point scale

Disequilibrium Visual Analog Scale ScoreWeeks 1, 4, 7, and 18

The investigator will measure the sense of disequilibrium while the participant walks 20' on separate visual analog scales. The distance from the zero anchor to the respondent's marking will be measured without units but to the nearest tenth.

The response for the scale will be transformed to a 100-point scale.

Global Perception of Effect ScoreWeeks 1, 4, 7, and 18

The investigator will assess perception of change retrospectively across the entire study period with ratings using an 11-point Likert scale with anchors of "very much better" and "very much worse" with a middle point labeled "no change" to assess the magnitude of change in symptoms.

Trial Locations

Locations (1)

Emory Univeristy

🇺🇸

Atlanta, Georgia, United States

© Copyright 2025. All Rights Reserved by MedPath